Ethnic Diversity and Warfarin Pharmacogenomics.

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Health Disparities

Background:

• Warfarin, a widely prescribed vitamin K antagonist, presents dosing challenges due to its narrow therapeutic window and significant interpatient variability.
• Extensive research has explored genotype-phenotype relationships for warfarin dosing, yet most studies focus on White and Asian populations.
• This lack of ethnic diversity in pharmacogenomic research may limit the applicability of current dosing algorithms to underrepresented groups.

Purpose of the Study:

• To assess the representation of different racial and ethnic groups in the existing body of pharmacogenomic evidence for warfarin.
• To evaluate the potential impact of ethnic underrepresentation on the clinical utility and effectiveness of warfarin pharmacogenomic dosing algorithms.
• To highlight how current evidence may exacerbate health inequalities in anticoagulation management.

Main Methods:

• Systematic review of published pharmacogenomic dosing algorithms for warfarin.
• Inclusion of studies examining clinical utility, cost-effectiveness, and implementation guidelines related to warfarin pharmacogenomics.
• Analysis of the racial and ethnic demographics reported in the selected studies.

Main Results:

• The majority of published warfarin pharmacogenomic studies and dosing algorithms have been conducted in White and Asian populations.
• Evidence regarding the performance of these algorithms in underrepresented populations (Blacks, Hispanics/Latinos, Indigenous peoples, Pacific Islanders) is limited.
• Differences in minor allele frequencies of key genetic variants across ethnic groups suggest that algorithms validated in Whites/Asians may not translate effectively.

Conclusions:

• Current pharmacogenomic evidence for warfarin dosing lacks ethnic diversity, potentially leading to suboptimal anticoagulation and health disparities.
• Validated pharmacogenomic dosing algorithms may not perform equitably across all racial and ethnic groups.
• Further research is needed to develop and validate warfarin dosing strategies that account for diverse genetic backgrounds to ensure equitable patient care.